Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Chugai to Discontinue Sale of Rocaltrol in Japan
November 7, 2024
- Nxera Pharma Eyes 50 Billion Yen in Global Revenue by 2030: CEO
November 7, 2024
- Fujifilm CDMO Unit’s New Bioreactors Now Up and Running in Denmark
November 6, 2024
- Eisai and Taiho VC Firms Certified for AMED Startup Project
November 6, 2024
- Konica Minolta Unloads Ambry as It Pivots Away from Precision Biz
November 6, 2024
- Orion Starts Sales of Divigel as Its 1st Product in Japan
November 6, 2024
- AZ, Kyoto University to Study Pharmacovigilance Using RWD
November 5, 2024
- GRP Japan Acquires Hypoglycemia Drug Baqsimi from Lilly
November 5, 2024
- Meiji Seika Pharma “Preparing” to Sue CDP’s Haraguchi
November 5, 2024
- ROS1 Drug Effective in Japanese Subgroup: Nippon Kayaku
November 5, 2024
- Mitsubishi Tanabe Sales Up 6% on Radicava Oral Form
November 5, 2024
- Santen’s Glaucoma Med Rhopressa Hits Shelves in South Korea
November 5, 2024
- Mitsubishi to Take Another Stab at Parkinson’s Drug Submission in US
November 5, 2024
- LEO Pharma, Kyowa Kirin to Wind Up Dovobet Collaboration
November 5, 2024
- FDA Rolling Submission for Leqembi SC Completed: Eisai
November 5, 2024
- Takeda’s Japan Sales Ratio Falls Below 10%, Global Biz Thrives in H1
November 1, 2024
- Daiichi Sankyo Ups Outlook on Earnings Growth Driven by Enhertu
November 1, 2024
- Ono President Hopes to Turn Deciphera into Black in 2-3 Years
November 1, 2024
- Daiichi Sankyo Starts 3 Global PIII Trials of TROP2 ADC for NSCLC
November 1, 2024
- Kyowa Kirin Picks Abdul Mullick as New President and COO
November 1, 2024
ページ
Japan is opening a new chapter in sleep medicine. The recent decision to allow medical institutions to advertise “sleep disorders”…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…